41 results on '"Scorsetti M."'
Search Results
2. Manual Superficial Keratectomy Is the First Choice Treatment for Salzmann Nodular Degeneration
- Author
-
Scorsetti, M. Micaela, Eguiza, V. Sergio, and Durán, Juan A.
- Published
- 2024
- Full Text
- View/download PDF
3. Definitive results of a prospective non-randomized phase 2 study on stereotactic body radiation therapy (sbrt) for medically inoperable lung and liver oligometastases from breast cancer
- Author
-
Franceschini, D., Franzese, C., Comito, T., Ilieva, M.B., Spoto, R., Marzo, A.M., Dominici, L., Massaro, M., Bellu, L., Badalamenti, M., Mancosu, P., and Scorsetti, M.
- Published
- 2024
- Full Text
- View/download PDF
4. Adjuvant Hypofractionated Whole Breast Irradiation (WBI) vs. Accelerated Partial Breast Irradiation (APBI) in Postmenopausal Women with Early Stage Breast Cancer: 5Years Update of the HYPAB Trial
- Author
-
Lo Faro, L., Fogliata, A., Franceschini, D., Spoto, R., Dominici, L., Bertolini, A., Stefanini, S., Vernier, V., Ilieva, M.B., and Scorsetti, M.
- Published
- 2024
- Full Text
- View/download PDF
5. Oligometastatic sarcoma treated with Curative intent Ablative Radiotherapy (OSCAR): A multicenter study on behalf of AIRO (Italian association of Radiotherapy and clinical Oncology)
- Author
-
Franceschini, D., Greto, D., Dicuonzo, S., Navarria, F., Federico, M., La Vecchia, M., Sangalli, C., Allajbej, A., Di Cristina, L., Mazzola, R., Pontoriero, A., Montesi, G., Navarria, P., Baldaccini, D., Clerici, E., Lo Faro, L., Franzese, C., Di Biase, S., Pergolizzi, S., Alongi, F., Bignardi, M., Fazio, I., Mascarin, M., Jereczek-Fossa, B.A., Livi, L., and Scorsetti, M.
- Published
- 2024
- Full Text
- View/download PDF
6. PSICHE trial (NCT05022914): PSMA guided approach for bIochemical relapse after prostatectomy- a prospective trial
- Author
-
Francolini, G., primary, Di Cataldo, V., additional, Garlatti, P., additional, Detti, B., additional, Bertini, N., additional, Ilaria, B., additional, Caini, S., additional, Franzese, C., additional, Scorsetti, M., additional, Simoni, N., additional, Colombo, F., additional, Chiti, A., additional, Serni, S., additional, Campi, R., additional, Minervini, A., additional, Vaggelli, L., additional, Burchini, L., additional, Frosini, G., additional, Loi, M., additional, Simontacchi, G., additional, Desideri, I., additional, Meattini, I., additional, Valicenti, R.K., additional, and Livi, L., additional
- Published
- 2024
- Full Text
- View/download PDF
7. PEACE V–Salvage Treatment of oligorecurrent nodal prostate cancer metastases (STORM): 24-months toxicity results of a randomized phase II trial
- Author
-
Zilli, T., primary, Shankar, S., additional, Brabrand, S., additional, Dirix, S., additional, Liefhooghe, S., additional, Otte, F-X., additional, Gomez-Iturriaga, A., additional, Everaerts, W., additional, Shelan, M., additional, Conde-Moreno, A., additional, López Campos, F., additional, Papachristofilou, A., additional, Guckenberger, M., additional, Scorsetti, M., additional, Zapatero, A., additional, Villafranca Iturre, A.E., additional, Eito, C., additional, Counago, F., additional, Muto, P., additional, Van De Voorde, L., additional, Mach, N., additional, Fonteyne, V., additional, Dries, R., additional, and Ost, P., additional
- Published
- 2024
- Full Text
- View/download PDF
8. Radiation therapy for locally advanced pancreatic adenocarcinoma: a therapeutic option which should not be forgotten. Letter to the Editor regarding: “Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up” by Huguet et al.
- Author
-
Huguet, F., Bouchart, C., Bruynzeel, A.M.E., Hawkins, M.A., Mukherjee, S., Nuyttens, J.J., Riou, O., Scorsetti, M., Versteijne, E., Loi, M., and Vendrely, V.
- Published
- 2024
- Full Text
- View/download PDF
9. Adjuvant Hypofractionated Whole Breast Irradiation (WBI) vs. Accelerated Partial Breast Irradiation (APBI) in Postmenopausal Women with Early Stage Breast Cancer: 5Years Update of the HYPAB Trial.
- Author
-
Faro, L. Lo, Fogliata, A., Franceschini, D., Spoto, R., Dominici, L., Bertolini, A., Stefanini, S., Vernier, V., Ilieva, M. B., and Scorsetti, M.
- Published
- 2024
- Full Text
- View/download PDF
10. SC13.05 KNOWLEDGE-BASED PLANNING OF TOTAL MARROW LYMPH-NODE IRRADIATION DELIVERED WITH VOLUMETRIC MODULATED ARC THERAPY.
- Author
-
Meraldi, M., Lambri, N., Bianchi, M., Bresolin, A., Buzzi, S., Dei, D., Gallo, P., La Fauci, F., Lobefalo, F., Paganini, L., Pelizzoli, M., Reggiori, G., Tatani, B., Tomatis, S., Zaccone, C., Scorsetti, M., Lenardi, C., and Mancosu, P.
- Published
- 2024
- Full Text
- View/download PDF
11. A0644 - PEACE V–Salvage Treatment of oligorecurrent nodal prostate cancer metastases (STORM): 24-months toxicity results of a randomized phase II trial.
- Author
-
Zilli, T., Shankar, S., Brabrand, S., Dirix, S., Liefhooghe, S., Otte, F-X., Gomez-Iturriaga, A., Everaerts, W., Shelan, M., Conde-Moreno, A., López Campos, F., Papachristofilou, A., Guckenberger, M., Scorsetti, M., Zapatero, A., Villafranca Iturre, A.E., Eito, C., Counago, F., Muto, P., and Van De Voorde, L.
- Subjects
- *
METASTASIS , *PROSTATE cancer , *PEACE - Published
- 2024
- Full Text
- View/download PDF
12. 146 (PB-053) Poster - The radiotherapy omission within the Sinodar One protocol: Survival and Relapse Outcomes and dosimetric analysis.
- Author
-
Spoto, R., Bertolini, A., Franceschini, D., Dominici, L., Lobefalo, F., Tinterri, C., and Scorsetti, M.
- Subjects
- *
RADIOTHERAPY , *CANCER relapse , *RADIATION dosimetry , *EVALUATION of medical care , *CONFERENCES & conventions , *TUMORS - Published
- 2024
- Full Text
- View/download PDF
13. 6 Mini Oral - Adjuvant Hypofractionated Whole Breast Irradiation (WBI) Versus Accelerated Partial Breast Irradiation (APBI) in Postmenopausal Women with Early Stage Breast Cancer: 5-Years Update of the HYPAB Trial.
- Author
-
Franceschini, D., Lo Faro, L., Fogliata, A., Spoto, R., Dominici, L., Bertolini, A., Franzese, C., and Scorsetti, M.
- Subjects
- *
RADIOTHERAPY , *BREAST tumors , *POSTMENOPAUSE , *CONFERENCES & conventions , *COMPUTERS in medicine , *TUMOR classification - Published
- 2024
- Full Text
- View/download PDF
14. A0600 - PSICHE trial (NCT05022914): PSMA guided approach for bIochemical relapse after prostatectomy- a prospective trial.
- Author
-
Francolini, G., Di Cataldo, V., Garlatti, P., Detti, B., Bertini, N., Ilaria, B., Caini, S., Franzese, C., Scorsetti, M., Simoni, N., Colombo, F., Chiti, A., Serni, S., Campi, R., Minervini, A., Vaggelli, L., Burchini, L., Frosini, G., Loi, M., and Simontacchi, G.
- Published
- 2024
- Full Text
- View/download PDF
15. Disruptions in antigen processing and presentation machinery on sarcoma.
- Author
-
Renne SL, Sama' L, Kumar S, Mintemur O, Ruspi L, Santori I, Sicoli F, Bertuzzi A, Laffi A, Bonometti A, Colombo P, D'amato V, Bressan A, Scorsetti M, Terracciano L, Navarria P, D'incalci M, Quagliuolo V, Pasqualini F, Grizzi F, and Cananzi FCM
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Adult, Antigens, Neoplasm immunology, Antigens, Neoplasm metabolism, Proteasome Endopeptidase Complex metabolism, beta 2-Microglobulin metabolism, Prognosis, ATP Binding Cassette Transporter, Subfamily B, Member 3, Sarcoma immunology, Sarcoma pathology, Antigen Presentation immunology
- Abstract
Background: The antigen processing machinery (APM) plays a critical role in generating tumor-specific antigens that can be recognized and targeted by the immune system. Proper functioning of APM components is essential for presenting these antigens on the surface of tumor cells, enabling immune detection and destruction. In many cancers, defects in APM can lead to immune evasion, contributing to tumor progression and poor clinical outcomes. However, the status of the APM in sarcomas is not well characterized, limiting the development of effective immunotherapeutic strategies for these patients., Methods: We investigated 126 patients with 8 types of bone and soft tissue sarcoma operated between 2001-2021. Tissue microarrays mapped 11 specific areas in each case. The presence/absence of APM protein was determined through immunohistochemistry. Bayesian networks were used., Results: All investigated sarcomas had some defects in APM. The least damaged component was HLA Class I subunit β2-microglobulin and HLA Class II. The proteasome LMP10 subunit was defective in leiomyosarcoma (LMS), myxoid liposarcoma (MLPS), and dedifferentiated liposarcoma (DDLPS), while MHC I transporting unit TAP2 was altered in undifferentiated pleomorphic sarcoma (UPS), gastrointestinal stromal tumor (GIST), and chordoma (CH). Among different neoplastic areas, high-grade areas showed different patterns of expression compared to high lymphocytic infiltrate areas. Heterogeneity at the patient level was also observed. Loss of any APM component was prognostic of distant metastasis (DM) for LMS and DDLPS and of overall survival (OS) for LMS., Conclusion: Sarcomas exhibit a high degree of defects in APM components, with differences among histotypes and tumoral areas. The most commonly altered APM components were HLA Class I subunit β2-microglobulin, HLA Class I subunit α (HC10), and MHC I transporting unit TAP2. The loss of APM components was prognostic of DM and OS and clinically relevant for LMS and DDLPS. This study explores sarcoma molecular mechanisms, enriching personalized therapeutic approaches., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
16. Mesenchymal Tumor Management: Integrating Surgical and Non-Surgical Strategies in Different Clinical Scenarios.
- Author
-
Samà L, Rodda GA, Ruspi L, Sicoli F, D'Amato V, Renne SL, Laffi A, Baldaccini D, Clerici E, Navarria P, Scorsetti M, Bertuzzi AF, Quagliuolo VL, and Cananzi FCM
- Abstract
Mesenchymal tumors originate from mesenchymal cells and can be either benign or malignant, such as bone, soft tissue, and visceral sarcomas. Surgery is a cornerstone treatment in the management of mesenchymal tumors, often requiring complex procedures performed in high-volume referral centers. However, the COVID-19 pandemic has highlighted this need for alternative non-surgical approaches due to limited access to surgical resources. This review explores the role of non-surgical treatments in different clinical scenarios: for improving surgical outcomes, as a bridge to surgery, as better alternatives to surgery, and for non-curative treatment when surgery is not feasible. We discuss the effectiveness of active surveillance, cryoablation, high-intensity focused ultrasound, and other ablative techniques in managing these tumors. Additionally, we examine the use of tyrosine kinase inhibitors in gastrointestinal stromal tumors and hypofractionated radiotherapy in soft tissue sarcomas. The Sarculator tool is highlighted for its role in stratifying high-risk sarcoma patients and personalizing treatment plans. While surgery remains the mainstay of treatment, integrating advanced non-surgical strategies can enhance therapeutic possibilities and patient care, especially in specific clinical settings with limitations. A multidisciplinary approach in referral centers is vital to determine the optimal treatment course for each patient.
- Published
- 2024
- Full Text
- View/download PDF
17. Predictive Factors for Long-Term Disease Control in Systemic Treatment-Naïve Oligorecurrent Renal Cell Carcinoma Treated with Up-Front Stereotactic Ablative Radiotherapy (SABR).
- Author
-
Franzese C, Vernier V, Badalamenti M, Lucchini R, Stefanini S, Bertolini A, Ilieva M, Di Cristina L, Marini B, Franceschini D, Comito T, Spoto R, Dominici L, Galdieri C, Mancosu P, Tomatis S, and Scorsetti M
- Abstract
Background: Stereotactic ablative radiotherapy (SABR) is emerging as a potential local treatment option for oligometastatic RCC. This study aims to evaluate the efficacy of SABR in patients with oligorecurrent RCC., Methods: A total of 50 patients with histologically confirmed RCC underwent SABR for oligorecurrence between 2006 and 2022. Eligible patients had up to five extracranial metastases and were systemic treatment-naïve at the time of irradiation. The primary endpoints of the analysis were overall survival (OS), local control (LC), distant metastasis-free survival (DMFS), and time to systemic therapy initiation., Results: The median OS was not reached, with 1- and 3-year OS rates of 93.8% and 77.5%, respectively. LC rates at one and three years were 95.8% and 86.5%, respectively. The median time to systemic therapy initiation was 63.8 months, and the median DMFS was 17.9 months, with one- and three-year rates of 63.4% and 36.6%, respectively. Multiple metastases were a negative predictive factor for DMFS (HR 2.39, p = 0.023), whereas lung metastases were associated with a more favorable outcome (HR 0.38, p = 0.011)., Conclusions: SABR offers a valuable treatment option for oligometastatic RCC, demonstrating significant potential for achieving long-term disease control and delaying the need for systemic therapy.
- Published
- 2024
- Full Text
- View/download PDF
18. Machine learning and lean six sigma for targeted patient-specific quality assurance of volumetric modulated arc therapy plans.
- Author
-
Lambri N, Dei D, Goretti G, Crespi L, Brioso RC, Pelizzoli M, Parabicoli S, Bresolin A, Gallo P, La Fauci F, Lobefalo F, Paganini L, Reggiori G, Loiacono D, Franzese C, Tomatis S, Scorsetti M, and Mancosu P
- Abstract
Background and Purpose: Radiotherapy plans with excessive complexity exhibit higher uncertainties and worse patient-specific quality assurance (PSQA) results, while the workload of measurement-based PSQA can impact the efficiency of the radiotherapy workflow. Machine Learning (ML) and Lean Six Sigma, a process optimization method, were implemented to adopt a targeted PSQA approach, aiming to reduce workload, risk of failures, and monitor complexity., Materials and Methods: Lean Six Sigma was applied using DMAIC (define, measure, analyze, improve, and control) steps. Ten complexity metrics were computed for 69,811 volumetric modulated arc therapy (VMAT) arcs from 28,612 plans delivered in our Institute (2013-2021). Outlier complexities were defined as >95th-percentile of the historical distributions, stratified by treatment. An ML model was trained to predict the gamma passing rate (GPR-3 %/1mm) of an arc given its complexity. A decision support system was developed to monitor the complexity and expected GPR. Plans at risk of PSQA failure, either extremely complex or with average GPR <90 %, were identified. The tool's impact was assessed after nine months of clinical use., Results: Among 1722 VMAT plans monitored prospectively, 29 (1.7 %) were found at risk of failure. Planners reacted by performing PSQA measurement and re-optimizing the plan. Occurrences of outlier complexities remained stable within 5 %. The expected GPR increased from a median of 97.4 % to 98.2 % (Mann-Whitney p < 0.05) due to plan re-optimization., Conclusions: ML and Lean Six Sigma have been implemented in clinical practice enabling a targeted measurement-based PSQA approach for plans at risk of failure to improve overall quality and patient safety., Competing Interests: Pietro Mancosu is an Editorial Board Member/Editor-in-Chief/Associate Editor/Guest Editor for Physics and Imaging in Radiation Oncology and was not involved in the editorial review or the decision to publish this article., (© 2024 The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
19. Stereotactic body radiotherapy for spinal oligometastases: a survey on patterns of practice on behalf of the Italian Association of Clinical Oncology and Radiotherapy (AIRO).
- Author
-
Cuccia F, Franzese C, Badellino S, Borghetti P, Federico M, Marvaso G, Montesi G, Pontoriero A, Ferrera G, Alongi F, and Scorsetti M
- Abstract
Background: The Study Group for the Biology and Treatment of the OligoMetastatic Disease on behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) has conducted a national survey with the aim to depict the current patterns of practice of stereotactic body radiotherapy (SBRT) for spinal oligometastases., Methods: The Surveymonkey platform was used to send a 28-items questionnaire focused on demographic, clinical and technical aspects related to SBRT for spinal oligometastases. All the AIRO members were invited to fill the questionnaire. Data were then centralized to a single center for analysis and interpretation., Results: 53 radiation oncologists from 47 centers fulfilled the survey. A complete agreement was observed in proposing SBRT for spinal oligometastases, with the majority considering up to 3 concurrent spine oligometastases feasible for SBRT (73.5%), regardless of spine site (70%), vertebral segment (85%) and morphological features of the lesion (71.7%). Regarding dose prescription, fractionated regimens resulted as the preferred option, either in 3 (58.4%) or five sessions (34%), with a substantial agreement in applying a PTV-margin larger than 1 mm (almost 90% of participants), and ideally using both MRI and PET imaging to improve target volume and organs-at-risk delineation (67.9%)., Conclusions: This national italian survey illustrates the patterns of practice and the main issues for the indication of SBRT for spinal oligometastases. A substantial agreement in the numerical cut-off and vertebral segment involved for SBRT indication was reported, with a slight heterogeneity in terms of dose prescription and fractionation schemes., (© 2024. The Author(s), under exclusive licence to Springer Nature B.V.)
- Published
- 2024
- Full Text
- View/download PDF
20. Response to Tugcu et al.
- Author
-
Desideri I, Morelli I, Banini M, Greto D, Visani L, Nozzoli F, Caini S, Della Puppa A, Livi L, Perini Z, Zivelonghi E, Bulgarelli G, Pinzi V, Navarria P, Clerici E, Scorsetti M, Ascolese AM, Osti MF, Anselmo P, Amelio D, Minniti G, and Scartoni D
- Abstract
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
- Published
- 2024
- Full Text
- View/download PDF
21. STRILL: Phase I Trial Evaluating Stereotactic Body Radiotherapy (SBRT) Dose Escalation for Re-Irradiation of Inoperable Peripheral Lung Lesions.
- Author
-
Franceschini D, Loi M, Marzo AM, Dominici L, Spoto R, Bertolini A, Lo Faro L, La Fauci F, Marini B, Di Cristina L, and Scorsetti M
- Abstract
Few data are available on the role of SBRT re-irradiation for isolated recurrences. We designed a prospective phase I study to evaluate the maximum tolerated dose (MTD) of SBRT for thoracic re-irradiation, for peripheral lung lesions. RT was delivered with a dose escalation design from 30 Gy in five fractions up to 50 Gy in five fractions. The primary end point was the definition of the maximum tolerated dose (MTD) of SBRT for thoracic re-irradiation. The dose-limiting toxicity was pneumonia ≥G3. Fifteen patients were enrolled. No cases of pneumonia ≥G3 occurred in any of our cohorts. Only one patient developed pneumonia G1 during treatment. Three patients developed acute toxicities that included dyspnea G1, cardiac failure G3, and chest wall pain. One patient developed G3 late toxicity with acute coronary syndrome. After a median follow-up of 21 months (range 3.6-29.1 months), six patients (40%) had a local relapse. Distant relapse occurred in five patients (33.3%). At the last follow-up, six patients died, all but two due to progressive disease. SBRT dose escalation for thoracic re-irradiation is an effective and well-tolerated option for patients with inoperable lung lesions after a first thoracic RT with acceptable acute and late toxicities.
- Published
- 2024
- Full Text
- View/download PDF
22. Repeated HyperArc radiosurgery for recurrent intracranial metastases and dosimetric analysis of recurrence pattern to account for diffuse dose effect on microscopical disease.
- Author
-
Nicosia L, Allegra AG, Giaj-Levra N, Bayani R, Darzikolaee NM, Mazzola R, Pastorello E, Ravelli P, Ricchetti F, Rigo M, Ruggieri R, Gurrera D, Borgese RF, Gaito S, Minniti G, Navarria P, Scorsetti M, and Alongi F
- Abstract
Aims: Evaluate effectiveness and safety of multiple HyperArc courses and patterns of progression in patients affected by BMs with intracranial progression., Methods: 56 patients were treated for 702 BMs with 197 (range 2-8) HyperArc courses in case of exclusive intracranial progression. Primary end-point was the overall survival (OS), secondary end-points were intracranial progression-free survival (iPFS), toxicity, local control (LC), neurological death (ND), and whole-brain RT (WBRT)-free survival. Site of progression was evaluated against isodoses levels (0, 1, 2, 3, 5, 7, 8, 10, 13, 15, 20, and 24 Gy.)., Results: The 1-year OS was 70 %, and the median was 20.8 months (17-36). At the univariate analysis (UVA) biological equivalent dose (BED) > 51.3 Gy and non-melanoma histology significantly correlated with OS. The median time to iPFS was 4.9 months, and the 1-year iPFS was 15 %. Globally, 538 new BMs occurred after the first HA cycle in patients with extracranial disease controlled. 96.4 % of them occurred within the isodoses range 0-7 Gy as follows: 26.6 % (0 Gy), 16.5 % (1 Gy), 16.5 % (2 Gy), 20.1 % (3 Gy), 13.1 % (5 Gy), 3.4 % (7 Gy) (p = 0.00). Radionecrosis occurred in 2 metastases (0.28 %). No clinical toxicity of grade 3 or higher occurred during follow-up. One- and 2-year LC was 90 % and 79 %, respectively. At the UVA BED > 70 Gy and non-melanoma histology were significant predictors of higher LC. The 2-year WBRT-free survival was 70 %. After a median follow-up of 17.4 months, 12 patients deceased by ND., Conclusion: Intracranical relapses can be safely and effectively treated with repeated HyperArc, with the aim to postpone or avoid WBRT. Diffuse dose by volumetric RT might reduce microscopic disease also at relatively low levels, potentially acting as a virtual CTV . Neurological death is not the most common cause of death in this population, which highlights the impact of extracranial disease on overall survival., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2024 The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
23. Translating knowledge into policy: Organizational model and minimum requirements for the implementation of a regional pancreas unit network.
- Author
-
Balzano G, Reni M, Di Bartolomeo M, Scorsetti M, Caraceni A, Rivizzigno P, Amorosi A, Scardoni A, Abu Hilal M, Ferrari G, Labianca R, Venturini M, Doglioni C, Riva L, Caccialanza R, and Carrara S
- Abstract
Pancreatic and periampullary cancers pose significant challenges in oncological care due to their complexity and diagnostic difficulties. Global experiences underscore the crucial role of multidisciplinary collaboration and centralized care in improving patient outcomes in this context. Recognizing these challenges, Lombardy, Italy's most populous region, embarked on establishing pancreas units across its territory to enhance clinical outcomes and organizational efficiency. This initiative, driven by a multistakeholder approach involving the Lombardy Welfare Directorate, clinicians, and a patient association, emphasizes the centralization of complex care in high-volume hospitals, adopting a hub-and-spoke model and a multidisciplinary approach. This article outlines the process and criteria set forth for pancreas unit implementation, aiming to provide a structured framework for enhancing pancreatic cancer care. Central to this initiative is the establishment of structured criteria and minimal requirements, not only for surgery but also for other essential components of care, ensuring a comprehensive approach to pancreatic cancer management. The Lombardy model offers a structured framework for enhancing pancreatic cancer care, with potential applicability to other regions and countries seeking to improve their cancer care infrastructure., Competing Interests: Declaration of competing interest The following authors declare conflict of interest: Other authors declare no conflicts of interest, (Copyright © 2024 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
24. Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E 2 -RADIatE OligoCare study.
- Author
-
Christ SM, Alongi F, Ricardi U, Scorsetti M, Livi L, Balermpas P, Lievens Y, Braam P, Jereczek-Fossa BA, Stellamans K, Ratosa I, Widder J, Peulen H, Dirix P, Bral S, Ramella S, Hemmatazad H, Khanfir K, Geets X, Jeene P, Zilli T, Fournier B, Ivaldi GB, Clementel E, Fortpied C, Oppong FB, Ost P, and Guckenberger M
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Neoplasm Metastasis, Lung Neoplasms radiotherapy, Lung Neoplasms pathology, Radiotherapy Dosage, Breast Neoplasms pathology, Breast Neoplasms radiotherapy, Colorectal Neoplasms pathology, Colorectal Neoplasms radiotherapy, Carcinoma, Non-Small-Cell Lung radiotherapy, Carcinoma, Non-Small-Cell Lung pathology, Aged, 80 and over, Prostatic Neoplasms radiotherapy, Prostatic Neoplasms pathology, Neoplasms radiotherapy, Neoplasms pathology, Radiosurgery methods, Dose Fractionation, Radiation
- Abstract
Background and Introduction: Optimal dose and fractionation in stereotactic body radiotherapy (SBRT) for oligometastatic cancer patients remain unknown. In this interim analysis of OligoCare, we analyzed factors associated with SBRT dose and fractionation., Materials and Methods: Analysis was based on the first 1,099 registered patients. SBRT doses were converted to biological effective doses (BED) using α/β of 10 Gy for all primaries, and cancer-specific α/β of 10 Gy for non-small cell lung and colorectal cancer (NSCLC, CRC), 2.5 Gy for breast cancer (BC), or 1.5 Gy for prostate cancer (PC)., Results: Of the interim analysis population of 1,099 patients, 999 (99.5 %) fulfilled inclusion criteria and received metastasis-directed SBRT for NSCLC (n = 195; 19.5 %), BC (n = 163; 16.3 %), CRC (n = 184; 18.4 %), or PC (n = 457; 47.5 %). Two thirds of patients were treated for single metastasis. Median number of fractions was 5 (IQR, 3-5) and median dose per fraction was 9.7 (IQR, 7.7-12.4) Gy. The most frequently treated sites were non-vertebral bone (22.8 %), lung (21.0 %), and distant lymph node metastases (19.0 %). On multivariate analysis, the dose varied significantly for primary cancer type (BC: 237.3 Gy BED, PC 300.6 Gy BED, and CRC 84.3 Gy BED), and metastatic sites, with higher doses for lung and liver lesions., Conclusion: This real-world analysis suggests that SBRT doses are adjusted to the primary cancers and oligometastasis location. Future analysis will address safety and efficacy of this site- and disease-adapted SBRT fractionation approach (NCT03818503)., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: BAJF received grants from Accuray, AIRC, IBA and Fondazione IEO-CCM, lecture payments/honoraria from Bayer, Accuray, Astellas, IBA, IPSEN, Astra Zeneca, Tecnologie Avanzate, Recordati, and Novartis, and has board appointments at Astra Zeneca, Bayer, and Seagen. MG and PO are PIs of the ESTRO-EORTC 1811-E²-RADIatE OligoCare trial. MG is president-elect of ESTRO., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
25. PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial.
- Author
-
Ost P, Siva S, Brabrand S, Dirix P, Liefhooghe N, Otte FX, Gomez-Iturriaga A, Everaerts W, Shelan M, Conde-Moreno A, López Campos F, Papachristofilou A, Guckenberger M, Scorsetti M, Zapatero A, Villafranca Iturre AE, Eito C, Couñago F, Muto P, Van De Voorde L, Mach N, Bultijnck R, Fonteyne V, Moon D, Thon K, Mercier C, Achard V, Stellamans K, Goetghebeur E, Reynders D, and Zilli T
- Subjects
- Humans, Male, Aged, Middle Aged, Neoplasm Recurrence, Local, Androgen Antagonists therapeutic use, Prostatic Neoplasms radiotherapy, Prostatic Neoplasms pathology, Prostatic Neoplasms therapy, Lymphatic Metastasis, Salvage Therapy
- Abstract
Background: Treatment recommendations for patients with limited nodal recurrences are lacking, and different locoregional treatment approaches are currently being used., Objective: The aim of this trial is to compare metastasis-directed therapy (MDT) with or without elective nodal pelvic radiotherapy (ENRT)., Design, Setting, and Participants: PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM) is an international, phase 2, open-label, randomized, superiority trial (ClinicalTrials.gov identifier: NCT03569241). Patients diagnosed with positron emission tomography-detected pelvic nodal oligorecurrence (five or fewer nodes) following radical local treatment for prostate cancer were randomized in a 1:1 ratio between arm A (MDT and 6 mo of androgen deprivation therapy [ADT]) and arm B (ENRT [25 × 1.8 Gy] with MDT and 6 mo of ADT)., Outcome Measurements and Statistical Analysis: We report the secondary endpoint acute toxicity, defined as worst grade ≥2 Common Terminology Criteria for Adverse Events v4.0 gastrointestinal (GI) or genitourinary (GU) toxicity within 3 mo of treatment. The chi-square test was used to compare toxicity between treatment arms. We also compare the quality of life (QoL) using the European Organisation for Research and Treatment of Cancer QLQ C30 and PR25 questionnaires., Results and Limitations: Between June 2018 and April 2021, 196 patients were assigned randomly to MDT or ENRT. Ninety-seven of 99 patients allocated to MDT and 93 of 97 allocated to ENRT received per-protocol treatment. Worst acute GI toxicity proportions were as follows: grade ≥2 events in three (3%) in the MDT group versus four (4%) in the ENRT group (p = 0.11). Worst acute GU toxicity proportions were as follows: grade ≥2 events in eight (8%) in the MDT group versus 12 (13%) in the ENRT group (p = 0.95). We observed no significant difference between the study groups in the proportion of patients with a clinically significant QoL reduction from baseline for any subdomain score area., Conclusions: No clinically meaningful differences were observed in worst grade ≥2 acute GI or GU toxicity or in QoL subdomains between MDT and ENRT., Patient Summary: We found no evidence of differential acute bowel or urinary side effects using metastasis-directed therapy and elective nodal radiotherapy for the treatment of patients with a pelvic lymph node recurrence., (Copyright © 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
26. Re-irradiation for recurrent intracranial meningiomas: Analysis of clinical outcomes and prognostic factors.
- Author
-
Desideri I, Morelli I, Banini M, Greto D, Visani L, Nozzoli F, Caini S, Della Puppa A, Livi L, Perini Z, Zivelonghi E, Bulgarelli G, Pinzi V, Navarria P, Clerici E, Scorsetti M, Ascolese AM, Osti MF, Anselmo P, Amelio D, Minniti G, and Scartoni D
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Adult, Aged, 80 and over, Prognosis, Young Adult, Treatment Outcome, Retrospective Studies, Meningioma radiotherapy, Meningioma pathology, Meningioma mortality, Re-Irradiation methods, Re-Irradiation adverse effects, Neoplasm Recurrence, Local radiotherapy, Meningeal Neoplasms radiotherapy, Meningeal Neoplasms pathology, Meningeal Neoplasms mortality
- Abstract
Purpose: Re-irradiation (re-RT) for recurrent intracranial meningiomas is hindered by the limited radiation tolerance of surrounding tissue and the risk of side effects. This study aimed at assessing outcomes, toxicities and prognostic factors in a cohort of patients with recurrent meningiomas re-treated with different RT modalities., Materials and Methods: A multi-institutional database from 8 Italian centers including intracranial recurrent meningioma (RM) patients who underwent re-RT with different modalities (SRS, SRT, PT, EBRT) was collected. Biologically Equivalent Dose in 2 Gy-fractions (EQD2) and Biological Effective Dose (BED) for normal tissue and tumor were estimated for each RT course (α/β = 2 for brain tissue and α/β = 4 for meningioma). Primary outcome was second progression-free survival (s-PFS). Secondary outcomes were overall survival (OS) and treatment-related toxicity. Kaplan-Meier curves and Cox regression models were used for analysis., Results: Between 2003 and 2021 181 patients (pts) were included. Median age at re-irradiation was 62 (range 20-89) and median Karnofsky Performance Status (KPS) was 90 (range 60-100). 78 pts were identified with WHO grade 1 disease, 65 pts had grade 2 disease and 10 pts had grade 3 disease. 28 pts who had no histologic sampling were grouped with grade 1 patients for further analysis. Seventy-five (41.4 %) patients received SRS, 63 (34.8 %) patients SRT, 31 (17.1 %) PT and 12 (6.7 %) EBRT. With a median follow-up of 4.6 years (interquartile range 1.7-6.8), 3-year s-PFS was 51.6 % and 3-year OS 72.5 %. At univariate analysis, SRT (HR 0.32, 95 % CI 0.19-0.55, p < 0.001), longer interval between the two courses of irradiation (HR 0.37, 95 % CI 0.21-0.67, p = 0.001), and higher tumor BED (HR 0.45 95 % CI 0.27-0.76, p = 0.003) were associated with longer s-PFS; in contrast, Ki67 > 5 % (HR 2.81, 95 % CI 1.48-5.34, p = 0.002) and WHO grade > 2 (HR 3.08, 95 % CI 1.80-5.28, p < 0.001) were negatively correlated with s-PFS. At multivariate analysis, SRT, time to re-RT and tumor BED maintained their statistically significant prognostic impact on s-PFS (HR 0.36, 95 % CI 0.21-0.64, p < 0.001; HR 0.38, 95 % CI 0.20-0.72, p = 0.003 and HR 0.31 95 % CI 0.13-0.76, p = 0.01, respectively). Acute and late adverse events (AEs) were reported in 38 (20.9 %) and 29 (16 %) patients. Larger tumor GTV (≥10 cc) was significantly associated with acute and late toxicity (p < 0.001 and p = 0.009, respectively)., Conclusions: In patients with recurrent meningiomas, reirradiation is a feasible treatment option associated with acceptable toxicity profile. Prognostic factors in the decision-making process have been identified and should be incorporated in daily practice., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
27. Deep learning-based optimization of field geometry for total marrow irradiation delivered with volumetric modulated arc therapy.
- Author
-
Lambri N, Longari G, Loiacono D, Brioso RC, Crespi L, Galdieri C, Lobefalo F, Reggiori G, Rusconi R, Tomatis S, Bellu L, Bramanti S, Clerici E, De Philippis C, Dei D, Navarria P, Carlo-Stella C, Franzese C, Scorsetti M, and Mancosu P
- Subjects
- Humans, Radiotherapy Dosage, Deep Learning, Radiotherapy, Intensity-Modulated methods, Radiotherapy Planning, Computer-Assisted methods, Bone Marrow radiation effects
- Abstract
Background: Total marrow (lymphoid) irradiation (TMI/TMLI) is a radiotherapy treatment used to selectively target the bone marrow and lymph nodes in conditioning regimens for allogeneic hematopoietic stem cell transplantation. A complex field geometry is needed to cover the large planning target volume (PTV) of TMI/TMLI with volumetric modulated arc therapy (VMAT). Five isocenters and ten overlapping fields are needed for the upper body, while, for patients with large anatomical conformation, two specific isocenters are placed on the arms. The creation of a field geometry is clinically challenging and is performed by a medical physicist (MP) specialized in TMI/TMLI., Purpose: To develop convolutional neural networks (CNNs) for automatically generating the field geometry of TMI/TMLI., Methods: The dataset comprised 117 patients treated with TMI/TMLI between 2011 and 2023 at our Institute. The CNN input image consisted of three channels, obtained by projecting along the sagittal plane: (1) average CT pixel intensity within the PTV; (2) PTV mask; (3) brain, lungs, liver, bowel, and bladder masks. This "averaged" frontal view combined the information analyzed by the MP when setting the field geometry in the treatment planning system (TPS). Two CNNs were trained to predict the isocenters coordinates and jaws apertures for patients with (CNN-1) and without (CNN-2) isocenters on the arms. Local optimization methods were used to refine the models output based on the anatomy of the patient. Model evaluation was performed on a test set of 15 patients in two ways: (1) by computing the root mean squared error (RMSE) between the CNN output and ground truth; (2) with a qualitative assessment of manual and generated field geometries-scale: 1 = not adequate, 4 = adequate-carried out in blind mode by three MPs with different expertise in TMI/TMLI. The Wilcoxon signed-rank test was used to evaluate the independence of the given scores between manual and generated configurations (p < 0.05 significant)., Results: The average and standard deviation values of RMSE for CNN-1 and CNN-2 before/after local optimization were 15 ± 2/13 ± 3 mm and 16 ± 2/18 ± 4 mm, respectively. The CNNs were integrated into a planning automation software for TMI/TMLI such that the MPs could analyze in detail the proposed field geometries directly in the TPS. The selection of the CNN model to create the field geometry was based on the PTV width to approximate the decision process of an experienced MP and provide a single option of field configuration. We found no significant differences between the manual and generated field geometries for any MP, with median values of 4 versus 4 (p = 0.92), 3 versus 3 (p = 0.78), 4 versus 3 (p = 0.48), respectively. Starting from October 2023, the generated field geometry has been introduced in our clinical practice for prospective patients., Conclusions: The generated field geometries were clinically acceptable and adequate, even for an MP with high level of expertise in TMI/TMLI. Incorporating the knowledge of the MPs into the development cycle was crucial for optimizing the models, especially in this scenario with limited data., (© 2024 The Authors. Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine.)
- Published
- 2024
- Full Text
- View/download PDF
28. Stereotactic Body Radiation Therapy for Oligoprogressive Pleural Mesothelioma: Fine-Tuning the Optimal Doses.
- Author
-
Ghirardelli P, Costantino G, Franceschini D, Villa E, Guaineri A, Scorsetti M, Vavassori V, and Ceresoli GL
- Abstract
There is growing evidence of a role of stereotactic body radiation therapy (SBRT) in the treatment of patients with oligoprogressive pleural mesothelioma (PM). The objective of this study was to investigate the optimal radiation therapy doses and schedules in this setting. The records of patients treated with SBRT (>5 Gy per fraction) for oligoprogression of PM at 2 institutions from June 2014 to September 2022 were reviewed. Patients were divided into 2 groups: "intermediate-dose" SBRT (i-SBRT; total dose, 30-36 Gy in 5-6 fractions) and "high-dose" SBRT (h-SBRT; total dose, 45-50 Gy in 4-8 fractions). The comparison between the 2 groups in terms of local control (LC) and toxicity was the primary endpoint of the study. Overall, 23 patients were treated for 25 pleural lesions. All had received upfront chemotherapy with platinum/pemetrexed. Fifteen patients were treated with i-SBRT and 8 patients with h-SBRT. The median equivalent dose was 40 Gy (range, 40-49.6) in the i-SBRT group and 74.46 Gy (range, 64-88) in the h-SBRT group. Six-month, 1-year, and 2-year LC were 100%, 100%, and 80% in the i-SBRT group and 100%, 100%, and 67% in the h-SBRT group, respectively (p =.94). Only 2 patients (1 for each dose group) had a recurrence in the radiation therapy field, both after experiencing a distant relapse. No severe acute and late toxicities were observed in the i-SBRT group, whereas in the h-SBRT group, 2 patients experienced G2 acute and late thoracic pain and 1 patient experienced G2 acute and G3 chronic thoracic pain. In our experience, SBRT is a safe and effective option for selected patients with oligoprogressive PM. Use of intermediate total doses keeping the dose per fraction high seems to offer an excellent LC, avoiding the risk of severe toxicity., Competing Interests: Disclosures Giovanni Luca Ceresoli declares advisory roles and speaker engagements with Novocure, Bristol-Myers Squibb, AstraZeneca, Novartis, Merck Sharp & Dohme, Bayer, and Astellas. The other authors declare no conflict of interest., (Copyright © 2024 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
29. ONE SHOT - single shot radiotherapy for localized prostate cancer: 18-month results of a single arm, multicenter phase I/II trial.
- Author
-
Zilli T, Franzese C, Guckenberger M, Giaj-Levra N, Mach N, Koutsouvelis N, Achard V, Mcdonald A, Alongi F, Scorsetti M, Constantin G, Bertaut A, and Miralbell R
- Subjects
- Humans, Male, Aged, Middle Aged, Prospective Studies, Aged, 80 and over, Quality of Life, Urethra radiation effects, Organ Sparing Treatments methods, Radiation Injuries etiology, Prostatic Neoplasms radiotherapy, Prostatic Neoplasms pathology, Prostatic Neoplasms surgery, Radiosurgery methods, Radiosurgery adverse effects
- Abstract
Purpose: To assess in a prospective, multicenter, single-arm phase I/II study the early safety and efficacy profile of single fraction urethra-sparing stereotactic body radiotherapy (SBRT) for men with localized prostate cancer., Material and Methods: Patients with low- and intermediate-risk localized prostate cancer without significant tumor in the transitional zone were recruited. A single-fraction of 19 Gy was delivered to the prostate, with 17 Gy dose-reduction to the urethra. Intrafraction motion was monitored using intraprostatic electromagnetic transponders with intra-fraction correction of displacements exceeding 3 mm. Genitourinary (GU), gastrointestinal (GI), and sexual toxicity during the first 18 months were evaluated using the CTCAE v4.0 grading scale. Quality of life was assessed using the International Prostate Symptom Score, the Expanded Prostate Cancer Index composite 26 score, and the International Index of Erectile Function score., Results: Among the 45 patients recruited in 5 centers between 2017 and 2022, 43 received the single fraction without protocol deviations, and 34 had a minimal follow-up of 18 months. The worst GU toxicity was observed at day-5 after SBRT (42.5 % and 20 % with grade 1 and 2, respectively), returning to baseline at week-12 and month-6 (<3% with grade 2), with a 12 % grade 2 flare at month 18. Gl toxicity was mild in the acute phase, with no grade ≥ 2 events (12 % grade 1 at month 6). Grade-3 proctitis was observed in one patient at month 12, with < 3 % grade 2 toxicity at month 18. Mean GU and GI bother scores showed a decline at day 5, a complete recovery at month 6, and a flare between month 12 and 18. Mean PSA dropped from 6.2 ng/ml to 1.2 ng/ml at month 18 and 0.7 ng/ml at month 24. After a median follow-up time of 26 months, 3 biochemical failures (7 %) were observed at month 17, 21 and 30., Conclusions: In this multicenter phase I/II trial, we demonstrated that a 19 Gy single-fraction urethra-sparing SBRT is feasible and associated with an acceptable toxicity rate, mostly returning to the baseline at week-12 and with a symptoms flare between months 12 and 18. Longer follow-up is needed to assess the potential long-term adverse effects and the disease control efficacy., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
30. Supramaximal resection: retrospective study on IDH-wildtype Glioblastomas based on the new RANO-Resect classification.
- Author
-
Tropeano MP, Raspagliesi L, Bono BC, Baram A, Rossini Z, Franzini A, Navarria P, Clerici E, Bellu L, Simonelli M, Scorsetti M, Riva M, Politi LS, and Pessina F
- Subjects
- Humans, Retrospective Studies, Middle Aged, Male, Female, Aged, Adult, Neurosurgical Procedures methods, Glioblastoma surgery, Glioblastoma pathology, Glioblastoma genetics, Glioblastoma mortality, Brain Neoplasms surgery, Brain Neoplasms pathology, Brain Neoplasms mortality, Brain Neoplasms diagnostic imaging, Isocitrate Dehydrogenase genetics
- Abstract
Background: The prognostic value of the extent of resection in the management of Glioblastoma is a long-debated topic, recently widened by the 2022 RANO-Resect Classification, which advocates for the resection of the non-enhancing disease surrounding the main core of tumors (supramaximal resection, SUPR) to achieve additional survival benefits. We conducted a retrospective analysis to corroborate the role of SUPR by the RANO-Resect Classification in a single center, homogenous cohort of patients., Methods: Records of patients operated for WHO-2021 Glioblastomas at our institution between 2007 and 2018 were retrospectively reviewed; volumetric data of resected lesions were computed and classified by RANO-Resect criteria. Survival and correlation analyses were conducted excluding patients below near-total resection., Results: 117 patients met the inclusion criteria, encompassing 45 near-total resections (NTR), 31 complete resections (CR), and 41 SUPR. Median progression-free and overall survival were 11 and 15 months for NTR, 13 and 17 months or CR, 20 and 24 months for SUPR, respectively (p < 0.001), with inverse correlation observed between survival and FLAIR residual volume (r -0.28). SUPR was not significantly associated with larger preoperative volumes or higher rates of postoperative deficits, although it was less associated with preoperative neurological deficits (OR 3.37, p = 0.003). The impact of SUPR on OS varied between MGMT unmethylated (HR 0.606, p = 0.044) and methylated (HR 0.273, p = 0.002) patient groups., Conclusions: Results of the present study support the validity of supramaximal resection by the new RANO-Resect classification, also highlighting a possible surgical difference between tumors with methylated and unmethylated MGMT promoter., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
31. Mapping the research landscape of HPV-positive oropharyngeal cancer: a bibliometric analysis.
- Author
-
Ammirabile A, Mastroleo F, Marvaso G, Alterio D, Franzese C, Scorsetti M, Franco P, Giannitto C, and Jereczek-Fossa BA
- Subjects
- Humans, Cross-Sectional Studies, Bibliometrics, Databases, Factual, Papillomavirus Infections complications, Papillomavirus Infections epidemiology, Papillomavirus Infections therapy, Oropharyngeal Neoplasms diagnosis, Oropharyngeal Neoplasms epidemiology, Oropharyngeal Neoplasms therapy
- Abstract
Objective: The aim of the study is to evaluate the scientific interest, the collaboration patterns and the emerging trends regarding HPV+ OPSCC diagnosis and treatment., Materials and Methods: A cross-sectional bibliometric analysis of articles reporting on HPV+ OPSCC within Scopus database was performed and all documents published up to December 31th, 2022 were eligible for analysis. Outcomes included the exploration of key characteristics (number of manuscripts published per year, growth rate, top productive countries, most highly cited papers, and the most well-represented journals), collaboration parameters (international collaboration ratio and networks, co-occurrence networks), keywords analysis (trend topics, factorial analysis)., Results: A total of 5200 documents were found, published from March, 1987 to December, 2022. The number of publications increased annually with an average growth rate of 19.94%, reaching a peak of 680 documents published in 2021. The 10 most cited documents (range 1105-4645) were published from 2000 to 2012. The keywords factorial analysis revealed two main clusters: one on epidemiology, diagnosis, prevention and association with other HPV tumors; the other one about the therapeutic options. According to the frequency of keywords, new items are emerging in the last three years regarding the application of Artifical Intelligence (machine learning and radiomics) and the diagnostic biomarkers (circulating tumor DNA)., Conclusions: This bibliometric analysis highlights the importance of research efforts in prevention, diagnostics, and treatment strategies for this disease. Given the urgency of optimizing treatment and improving clinical outcomes, further clinical trials are needed to bridge unaddressed gaps in the management of HPV+ OPSCC patients., Competing Interests: Declaration of Competing Interest None declared, (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
32. The Use of Artificial Intelligence in Head and Neck Cancers: A Multidisciplinary Survey.
- Author
-
Giannitto C, Carnicelli G, Lusi S, Ammirabile A, Casiraghi E, De Virgilio A, Esposito AA, Farina D, Ferreli F, Franzese C, Frigerio GM, Lo Casto A, Malvezzi L, Lorini L, Othman AE, Preda L, Scorsetti M, Bossi P, Mercante G, Spriano G, Balzarini L, and Francone M
- Abstract
Artificial intelligence (AI) approaches have been introduced in various disciplines but remain rather unused in head and neck (H&N) cancers. This survey aimed to infer the current applications of and attitudes toward AI in the multidisciplinary care of H&N cancers. From November 2020 to June 2022, a web-based questionnaire examining the relationship between AI usage and professionals' demographics and attitudes was delivered to different professionals involved in H&N cancers through social media and mailing lists. A total of 139 professionals completed the questionnaire. Only 49.7% of the respondents reported having experience with AI. The most frequent AI users were radiologists (66.2%). Significant predictors of AI use were primary specialty (V = 0.455; p < 0.001), academic qualification and age. AI's potential was seen in the improvement of diagnostic accuracy (72%), surgical planning (64.7%), treatment selection (57.6%), risk assessment (50.4%) and the prediction of complications (45.3%). Among participants, 42.7% had significant concerns over AI use, with the most frequent being the 'loss of control' (27.6%) and 'diagnostic errors' (57.0%). This survey reveals limited engagement with AI in multidisciplinary H&N cancer care, highlighting the need for broader implementation and further studies to explore its acceptance and benefits., Competing Interests: The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.
- Published
- 2024
- Full Text
- View/download PDF
33. Deep learning and atlas-based models to streamline the segmentation workflow of total marrow and lymphoid irradiation.
- Author
-
Dei D, Lambri N, Crespi L, Brioso RC, Loiacono D, Clerici E, Bellu L, De Philippis C, Navarria P, Bramanti S, Carlo-Stella C, Rusconi R, Reggiori G, Tomatis S, Scorsetti M, and Mancosu P
- Subjects
- Humans, Radiotherapy Planning, Computer-Assisted, Bone Marrow diagnostic imaging, Lymphatic Irradiation, Workflow, Organs at Risk radiation effects, Deep Learning
- Abstract
Purpose: To improve the workflow of total marrow and lymphoid irradiation (TMLI) by enhancing the delineation of organs at risk (OARs) and clinical target volume (CTV) using deep learning (DL) and atlas-based (AB) segmentation models., Materials and Methods: Ninety-five TMLI plans optimized in our institute were analyzed. Two commercial DL software were tested for segmenting 18 OARs. An AB model for lymph node CTV (CTV_LN) delineation was built using 20 TMLI patients. The AB model was evaluated on 20 independent patients, and a semiautomatic approach was tested by correcting the automatic contours. The generated OARs and CTV_LN contours were compared to manual contours in terms of topological agreement, dose statistics, and time workload. A clinical decision tree was developed to define a specific contouring strategy for each OAR., Results: The two DL models achieved a median [interquartile range] dice similarity coefficient (DSC) of 0.84 [0.71;0.93] and 0.85 [0.70;0.93] across the OARs. The absolute median Dmean difference between manual and the two DL models was 2.0 [0.7;6.6]% and 2.4 [0.9;7.1]%. The AB model achieved a median DSC of 0.70 [0.66;0.74] for CTV_LN delineation, increasing to 0.94 [0.94;0.95] after manual revision, with minimal Dmean differences. Since September 2022, our institution has implemented DL and AB models for all TMLI patients, reducing from 5 to 2 h the time required to complete the entire segmentation process., Conclusion: DL models can streamline the TMLI contouring process of OARs. Manual revision is still necessary for lymph node delineation using AB models., (© 2024. Italian Society of Medical Radiology.)
- Published
- 2024
- Full Text
- View/download PDF
34. Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) - Part II - Non-surgical treatments.
- Author
-
Cabibbo G, Daniele B, Borzio M, Casadei-Gardini A, Cillo U, Colli A, Conforti M, Dadduzio V, Dionisi F, Farinati F, Gardini I, Giannini EG, Golfieri R, Guido M, Mega A, Cinquini M, Piscaglia F, Rimassa L, Romanini L, Pecorelli A, Sacco R, Scorsetti M, Viganò L, Vitale A, and Trevisani F
- Subjects
- Humans, Radiology, Interventional, Medical Oncology, Italy, Carcinoma, Hepatocellular surgery, Gastroenterology, Gastroenterologists, Liver Neoplasms surgery, Hepatitis, Organ Transplantation
- Abstract
Worldwide, hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death. The remarkable improvements in treating HCC achieved in the last years have increased the complexity of its management. Following the need to have updated guidelines on the multidisciplinary treatment management of HCC, the Italian Scientific Societies involved in the management of this cancer have promoted the drafting of a new dedicated document. This document was drawn up according to the GRADE methodology needed to produce guidelines based on evidence. Here is presented the second part of guidelines, focused on the multidisciplinary tumor board of experts and non-surgical treatments of HCC., Competing Interests: Conflict of interest Giuseppe Cabibbo: Bayer, Eisai, Ipsen, MSD, AstraZeneca, Roche. Bruno Daniele: Astrazeneca, IPSEN, EISAI, MSD, Roche, Amgen, Incyte, Sanofi Mauro Borzio: none Andrea Casadei-Gardini: AstraZeneca, Bayer, Eisai, Incyte, Ipsen, IQVIA, MSD, Roche, Servier Umberto Cillo: none Agostino Colli: none Massimiliano Conforti: none Vincenzo Dadduzio: MSD, Ipsen, AstraZeneca, Amgen Francesco Dionisi: none Fabio Farinati: none Ivan Gardini: none Edoardo Giovanni Giannini: Rita Golfieri: Bayer, Bracco, Astra Zeneca Maria Guido: none Andrea Mega: none Michela Cinquini: none Fabio Piscaglia: Astrazeneca, Bayer, Bracco, ESAOTE, EISAI, Exact Sciences, IPSEN, MSD, Roche, Samsung, Siemens Healthineers Lorenza Rimassa: LR reports consulting fees from AstraZeneca, Basilea, Bayer, BMS, Eisai, Exelixis, Genenta, Hengrui, Incyte, Ipsen, IQVIA, Lilly, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, Zymeworks; lecture fees from AstraZeneca, Bayer, Eisai, Gilead, Incyte, Ipsen, Merck Serono, Roche, Sanofi, Servier; travel expenses from AstraZeneca; research grants (to Institution) from Agios, AstraZeneca, BeiGene, Eisai, Exelixis, Fibro-gen, Incyte, Ipsen, Lilly, MSD, Nerviano Medical Sciences, Roche, Zymeworks Laura Romanini: none Anna Pecorelli: none Rodolfo Sacco: none Marta Scorsetti: none Luca Viganò: none Alessandro Vitale: none Franco Trevisani:AstraZeneca, Abbvie, Bayer, BMS, Eisai, Gilead, MSD, Roche, (Copyright © 2023 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
35. Long term update on toxicity and survival of a phase II trial of linac-based stereotactic body radiation therapy for low-intermediate risk prostate cancer.
- Author
-
D'Agostino GR, Badalamenti M, Stefanini S, Baldaccini D, Franzese C, Faro LL, Di Cristina L, Vernier V, Reggiori G, and Scorsetti M
- Subjects
- Humans, Male, Neoplasm Grading, Positron Emission Tomography Computed Tomography, Prostate-Specific Antigen, Prostatic Neoplasms pathology, Radiosurgery methods
- Abstract
Background: In 2016 we published a phase II study exploring safety and efficacy of Stereotactic Body Radiation Therapy (SBRT) delivered with Volumetric Modulated Arc Therapy (VMAT) and Flattening Filter Free (FFF) beams techniques in prostate cancer (PC) patients. We present herein the updated results on late toxicity and long-term survival., Methods: Patients enrolled in the study had a biopsy-confirmed localized PC and the features of a low- or intermediate-risk disease (National Comprehensive Network Criteria). The radiotherapy (RT) schedule consisted of 35 Gy delivered in five fractions every other day. Toxicities were registered according to the common toxicity adverse events v4.0. Biochemical recurrence was defined as an increase of prostate specific antigen after nadir, confirmed at least once. Local recurrence (LR) and distant metastases were detected either with Choline- or PSMA-PET/CT scans. Kaplan-Meier curves for Biochemical Recurrence-Free Survival (BFS), Local Control (LC), Distant Metastasis Free Survival (DMFS) and Cancer Specific Survival, were calculated by using MedCalc., Results: Ninety patients were submitted to SBRT between February 2012 and March 2015. Fifty-eight patients (64.5%) had a Gleason Score of 6, while 32 (35.5%) had a Gleason Score of 7. A late grade 1 Genito-Urinary toxicity was observed in 54.5% of patients while a grade 2 in 3.3%. A late Gastro-intestinal grade 1 toxicity was reported in 18.9% of patients, while a grade 2 in 2.2%. Erectile dysfunction was reported by 13% of patients No heavier toxicities were observed. At a median follow-up of 102 months, 5- and 8-year BFS were 93.0% and 84.4% respectively, 5- and 8-year LC were 95.2% and 87.0% respectively, 5- and 8-year DMFS were 95.3% and 88.4%, respectively., Conclusions: This long-term update confirms that SBRT is a valid therapeutic strategy for low-intermediate risk PC. RT with VMAT and FFF warrants optimal results in terms of toxicity and disease control., (© 2023 The Authors. The Prostate published by Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
36. Defining Minimum Treatment Parameters of Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma: An Expert Consensus.
- Author
-
Yanagihara TK, Tepper JE, Moon AM, Barry A, Molla M, Seong J, Torres F, Apisarnthanarax S, Buckstein M, Cardenes H, Chang DT, Feng M, Guha C, Hallemeier CL, Hawkins MA, Hoyer M, Iwata H, Jabbour SK, Kachnic L, Kharofa J, Kim TH, Kirichenko A, Koay EJ, Makishima H, Mases J, Meyer JJ, Munoz-Schuffenegger P, Owen D, Park HC, Saez J, Sanford NN, Scorsetti M, Smith GL, Wo JY, Yoon SM, Lawrence TS, Reig M, and Dawson LA
- Subjects
- Humans, Consensus, Ambulatory Care Facilities, Carbon, Carcinoma, Hepatocellular radiotherapy, Liver Neoplasms radiotherapy
- Abstract
Purpose: External beam radiation therapy (EBRT) is a highly effective treatment in select patients with hepatocellular carcinoma (HCC). However, the Barcelona Clinic Liver Cancer system does not recommend the use of EBRT in HCC due to a lack of sufficient evidence and intends to perform an individual patient level meta-analysis of ablative EBRT in this population. However, there are many types of EBRT described in the literature with no formal definition of what constitutes "ablative." Thus, we convened a group of international experts to provide consensus on the parameters that define ablative EBRT in HCC., Methods and Materials: Fundamental parameters related to dose, fractionation, radiobiology, target identification, and delivery technique were identified by a steering committee to generate 7 Key Criteria (KC) that would define ablative EBRT for HCC. Using a modified Delphi (mDelphi) method, experts in the use of EBRT in the treatment of HCC were surveyed. Respondents were given 30 days to respond in round 1 of the mDelphi and 14 days to respond in round 2. A threshold of ≥70% was used to define consensus for answers to each KC., Results: Of 40 invitations extended, 35 (88%) returned responses. In the first round, 3 of 7 KC reached consensus. In the second round, 100% returned responses and consensus was reached in 3 of the remaining 4 KC. The distribution of answers for one KC, which queried the a/b ratio of HCC, was such that consensus was not achieved. Based on this analysis, ablative EBRT for HCC was defined as a BED10 ≥80 Gy with daily imaging and multiphasic contrast used for target delineation. Treatment breaks (eg, for adaptive EBRT) are allowed, but the total treatment time should be ≤6 weeks. Equivalent dose when treating with protons should use a conversion factor of 1.1, but there is no single conversion factor for carbon ions., Conclusions: Using a mDelphi method assessing expert opinion, we provide the first consensus definition of ablative EBRT for HCC. Empirical data are required to define the a/b of HCC., Competing Interests: Disclosures Ted K. Yanagihara reports grants or contracts from the Radiation Oncology Institute and Lineberger Comprehensive Cancer Center; serving as an expert independent reviewer for the North Carolina Medical Board; and serving as an American Board of Radiology Maintenance of Certification online longitudinal assessment senior reviewer. Andrew M. Moon reports grants or contracts from the American Association for the Study of Liver Diseases, the American College of Gastroenterology, and the National Institutes of Health; consulting feeds from Target RWE; and serving on the American Association for the Study of Liver Diseases Practice Guidelines Committee. Aisling Barry reports honoria from Eisai. Ferran Torres reports grants or contracts from the Hospital Clinic Barcelona (IDIBAPS); consulting fees from Universal DX; and participation in the data safety monitoring board/advisory board of the Hospital Clinic Barcelona with partial support from Bayer. Daniel T. Chang reports grants or contracts from RefleXion Medical, ViewRay, Inc, Varian Medical Systems; honoraria for presentation from Varian Medical Systems; support for attending meetings and travel from Varian Medical Systems; and participation on data safety monitoring board for the SMART trial for ViewRay. Chandan Guha reports grants or contracts from the NIH, Janssen and Celldex; consulting fees from Janssen; participation in the data safety monitoring board or advisory board of the Focused Ultrasound Foundation; and is a founder of BioConvergent Health. Morten Hoyer reports honoraria from Novo Nordisk. Lisa Kachnic reports receiving grants or contracts from Varian Medical Systems; serving as an editor for UpToDate; participation on the data safety monitoring committee for Beta Innovations; and is a board member of the Radiation Therapy Oncology Group. Eugene J. Koay reports funding from the Department of Defense and National Institutes of Health; grants or contracts from Philips Healthcare, GE Healthcare, Stand up to Cancer, Project Purple, Elekta, Department of Defense; royalties from Taylor and Francis, LLC; consulting fees from RenovoRx, AstraZeneca, Augmenix, and Kallisio; honoraria for lectures from Apollo Cancer hospitals in Chnnai India, Bayer Healthcare, Philips Healthcare, and Aptitude Health; a patent pending for 3-dimensional printed oral stents; serving on the scientific medical advisory board of the International Cholangiocarcinoma Research Network; and stock ownership of Quantum Aurea Capital. Joel Mases reports grants or contracts from Boston Scientific and royalties or licenses from Springer and UpToDate. Pablo Munoz-Schuffenegger reports grants or contracts from the National Fund for Scientific and Technological Development, National Commission for Scientific and Technological Research, Government of Chile; honoraria for lectures from Bayer and Roche Pharma AG; serving on an advisory board for AstraZeneca; and serving on the advanced radiation therapy committee, International Association for the Study of Lung Cancer. Dawn Owen reports payment from UpToDate and receipt of goods/services from AstraZeneca and Varian Medical Systems. Marta Scorsetti reports grants or contracts from Varian Medical Systems, Sofar, and IPSEN. Jenniefer Y. Wo reports grants or contracts from Genentech. Maria Reig reports grants or contracts from Bayer, Ipsen, and ISCII; serving as a consultant or on advisory boards and/or receiving travel support from Bayer, BMS, Roche, Ipsen, AstraZeneca, Eisai, Geneos Therapeutics, UniveralDx, MSD and Lilly; receiving lecture fees from Bayer, BMS, Gilead, AstraZeneca, ROCHE and Lilly; receiving support for attending meetings and/or travel from Bayer, BMS, Roche, Ipsen, AstraZeneca, Eisai, MSD, and Lilly; and serving as EASL representative in UEG. Laura A. Dawson reports serving as chair of ASTRO., (Copyright © 2023. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
37. Sterotactic Ablative Radiotherapy in a Multicentric Series of Oligometastatic SCLC: The SAMOS Cohort.
- Author
-
Borghetti P, Facheris G, Ciammella P, Galaverni M, Granello L, Scotti V, Franceschini D, Romei A, Giaj Levra N, Federico M, La Vecchia M, Merlotti A, Sepulcri M, Piperno G, Marvaso G, Simoni N, Alì E, Pontoriero A, Cappelli A, Dionisi V, Menis J, Martino A, Vagge S, Canova S, Montesi G, Cuccia F, Boldrini L, Franzese C, Grisanti S, Bruni A, and Scorsetti M
- Subjects
- Humans, Middle Aged, Retrospective Studies, Kaplan-Meier Estimate, Proportional Hazards Models, Lung Neoplasms radiotherapy, Lung Neoplasms drug therapy, Radiosurgery adverse effects
- Abstract
Aims: SCLC is the most aggressive lung cancer histology with a 5-year OS <10%. At the diagnosis, almost two-thirds of the SCLC an Extended Disease presentation. Two randomized studies (CASPIAN and ImPower133) demonstrated an OS improvement, when immunotherapy was prescribed as maintenance therapy after standard chemotherapy. To date, SABR has had a limited indication in managing metastatic SCLC, although recent reports proposed it as a valid treatment option in selected patients. We propose a retrospective multicentric analysis of patients treated with SABR for oligometastatic SCLC., Method: Data of patients affected by oligometastatic-SCLC treated with SABR between 2017 and 2022 in 11 Italian centers were collected. Clinical and therapeutic variables together with OS and time to next treatment were analyzed. Univariate analysis with Kaplan-Meier curve were calculated, and log-rank test were applied. Cox proportional hazard model was used for multivariate analysis., Results: Data from 93 patients and 132 metastatic lesions were analyzed. The median age was 64 years (36-86) and all but 1 had Performance Status 0 or 1. Fifty-two patients presented ED at diagnosis. The first line treatment was radiochemotherapy in 42%, CHT alone in 24% and CHT-IO in 28%, others treatment accounts for 4% and only 2% of patients underwent best supportive care. Of the 132 lesions treated with SBRT 55 were in brain, 27 in lung, 11 in liver, 10 in lymph nodes, 8 in bones and 20 in adrenal gland. Median OS was 14 months, 1 year-OS and 2 years OS were 53% and 27%, respectively. The median TtNT was 14 months for the entire population. Of all the analyzed variables only, the anatomical site of the metastases and their number showed statistical significance in the univariate analysist, confirmed in the subsequent multivariate., Conclusion: SABR seems to play a role in delaying further systemic lines in oligometastatic disease and to extend the use of ongoing treatment in oligoprogressive state. Prospective studies are needed to confirm these findings., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
38. Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Meta-Analysis and International Stereotactic Radiosurgery Society Practice Guidelines.
- Author
-
Bae SH, Chun SJ, Chung JH, Kim E, Kang JK, Jang WI, Moon JE, Roquette I, Mirabel X, Kimura T, Ueno M, Su TS, Tree AC, Guckenberger M, Lo SS, Scorsetti M, Slotman BJ, Kotecha R, Sahgal A, Louie AV, and Kim MS
- Subjects
- Humans, Treatment Outcome, Retrospective Studies, Carcinoma, Hepatocellular pathology, Liver Neoplasms pathology, Radiosurgery adverse effects
- Abstract
This systematic review and meta-analysis reports on outcomes and hepatic toxicity rates after stereotactic body radiation therapy (SBRT) for liver-confined hepatocellular carcinoma (HCC) and presents consensus guidelines regarding appropriate patient management. Using the Preferred Reporting Items for Systemic Review and Meta-Analyses guidelines, a systematic review was performed from articles reporting outcomes at ≥5 years published before October 2022 from the Embase, MEDLINE, Cochrane, and Scopus databases with the following search terms: ("stereotactic body radiotherapy" OR "SBRT" OR "SABR" OR "stereotactic ablative radiotherapy") AND ("hepatocellular carcinoma" OR "HCC"). An aggregated data meta-analysis was conducted to assess overall survival (OS) and local control (LC) using weighted random effects models. In addition, individual patient data analyses incorporating data from 6 institutions were conducted as their own subgroup analyses. Seventeen observational studies, comprising 1889 patients with HCC treated with ≤9 SBRT fractions, between 2003 and 2019, were included in the aggregated data meta-analysis. The 3- and 5-year OS rates after SBRT were 57% (95% confidence interval [CI], 47%-66%) and 40% (95% CI, 29%-51%), respectively. The 3- and 5-year LC rates after SBRT were 84% (95% CI, 77%-90%) and 82% (95% CI, 74%-88%), respectively. Tumor size was the only prognostic factor for LC. Tumor size and region were significantly associated with OS. Five-year LC and OS rates of 79% (95% CI, 0.74-0.84) and 25% (95% CI, 0.20-0.30), respectively, were observed in the individual patient data analyses. Factors prognostic for improved OS were tumor size <3 cm, Eastern region, Child-Pugh score ≤B7, and the Barcelona Clinic Liver Cancer stage of 0 and A. The incidence of severe hepatic toxicity varied according to the criteria applied. SBRT is an effective treatment modality for patients with HCC with mature follow-up. Clinical practice guidelines were developed on behalf of the International Stereotactic Radiosurgery Society (ISRS)., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
39. Multidisciplinary Treatment of Hepatocellular Carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) - Part I - Surgical treatments.
- Author
-
Cabibbo G, Daniele B, Borzio M, Casadei-Gardini A, Cillo U, Colli A, Conforti M, Dadduzio V, Dionisi F, Farinati F, Gardini I, Giannini EG, Golfieri R, Guido M, Mega A, Minozzi S, Piscaglia F, Rimassa L, Romanini L, Pecorelli A, Sacco R, Scorsetti M, Viganò L, Vitale A, and Trevisani F
- Subjects
- Humans, Radiology, Interventional, Medical Oncology, Italy, Carcinoma, Hepatocellular surgery, Carcinoma, Hepatocellular complications, Gastroenterology, Gastroenterologists, Liver Neoplasms surgery, Liver Neoplasms complications, Hepatitis complications, Organ Transplantation
- Abstract
Worldwide, hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death. The remarkable improvements in treating HCC achieved in the last years have increased the complexity of HCC management. Following the need to have updated guidelines on the multidisciplinary treatment management of HCC, the Italian Scientific Societies involved in the management of this cancer have promoted the drafting of a new dedicated document. This document was drawn up according to the GRADE methodology needed to produce guidelines based on evidence. Here is presented the first part of guidelines, focused on the multidisciplinary tumor board of experts and surgical treatments of HCC., Competing Interests: Conflict of interest The authors declare that there are no conflicts of interest., (Copyright © 2023 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
40. Repeat Gamma Knife radiosurgery for recurrent trigeminal neuralgia in patients with multiple sclerosis: a single-center retrospective study.
- Author
-
Franzini A, Picozzi P, Baram A, Navarria P, Scorsetti M, Tomatis S, and Pessina F
- Subjects
- Humans, Retrospective Studies, Facial Pain, Trigeminal Neuralgia radiotherapy, Trigeminal Neuralgia surgery, Multiple Sclerosis complications, Radiosurgery
- Abstract
Purpose: Gamma Knife radiosurgery (GKRS) has emerged as an effective treatment option for trigeminal neuralgia (TN) in patients with multiple sclerosis (MS). To date, the outcomes of repeat GKRS for patients with TN and MS with recurrent pain have been investigated in a few patients. This study aims to report the outcomes and predictive factors of pain reduction for MS patients undergoing repeat GKRS for recurrent TN., Methods: Eighteen patients with MS underwent repeat GKRS for recurrent TN. A retrospective chart review and telephone interviews were conducted to determine background medical history, dosimetric data, and outcomes of the procedure. Facial pain and sensory function were evaluated using the Barrow Neurological Institute (BNI) scales., Results: Fifteen patients achieved a BNI pain score of IIIa or better, indicating pain reduction, within a median period of 21 days after repeat GKRS. The maximum dose for repeat GKRS ranged from 70 to 85 Gy. Pain recurred in 5 patients after a median period of 12 months after GKRS. Percentages of patients with pain reduction at 1, 2, 3, 5, and 7 years were 60%, 60%, 50%, 50%, and 50%, respectively. Older age at repeat GKRS predicted sustained pain reduction (P = 0.01). Seven patients developed facial sensory disturbances, which were bothersome in two patients., Conclusions: Repeat GKRS may be used as an effective treatment modality for prolonging the duration of pain reduction time in patients with MS and TN. After repeat GKRS, facial sensory disturbances are common; however, they are often not bothersome., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
41. Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS).
- Author
-
Siva S, Louie AV, Kotecha R, Barber MN, Ali M, Zhang Z, Guckenberger M, Kim MS, Scorsetti M, Tree AC, Slotman BJ, Sahgal A, and Lo SS
- Subjects
- Humans, Kidney, Prospective Studies, Carcinoma, Renal Cell radiotherapy, Carcinoma, Renal Cell surgery, Kidney Neoplasms radiotherapy, Kidney Neoplasms surgery, Radiosurgery adverse effects
- Abstract
Surgery is the standard of care for patients with primary renal cell carcinoma. Stereotactic body radiotherapy (SBRT) is a novel alternative for patients who are medically inoperable, technically high risk, or who decline surgery. Evidence for using SBRT in the primary renal cell carcinoma setting is growing, including several rigorously conducted prospective clinical trials. This systematic review was performed to assess the safety and efficacy of SBRT for primary renal cell carcinoma. Review results then formed the basis for the practice guidelines described, on behalf of the International Stereotactic Radiosurgery Society. 3972 publications were screened and 36 studies (822 patients) were included in the analysis. Median local control rate was 94·1% (range 70·0-100), 5-year progression-free survival was 80·5% (95% CI 72-92), and 5-year overall survival was 77·2% (95% CI 65-89). These practice guidelines addressed four key clinical questions. First, the optimal dose fractionation was 25-26 Gy in one fraction, or 42-48 Gy in three fractions for larger tumours. Second, routine post-treatment biopsy is not recommended as it is not predictive of patient outcome. Third, SBRT for primary renal cell carcinoma in a solitary kidney is safe and effective. Finally, guidelines for post-treatment follow-up are described, which include cross-axial imaging of the abdomen including both kidneys, adrenals, and surveillance of the chest initially every 6 months. This systematic review and practice guideline support the practice of SBRT for primary renal cell carcinoma as a safe and effective standard treatment option. Randomised trials with surgery and invasive ablative therapies are needed to further define best practice., Competing Interests: Declaration of interests AVL received payment or honoraria for lectures, presentations, speaker's bureaus, manuscript writing, or educational events from AstraZeneca, unrelated to the present work, during the past 36 months. ACT declares institutional research grants from Elekta, Varian, and Accuray; payment or honoraria for lectures, presentations, speaker's bureaus, manuscript writing, or educational events from Elekta, Accuray, and Janssen; support for attending meetings and travel from Elekta; non-renumerated participation on the KORTUC and NEPTUNES internal displacement monitoring centre; and leadership or a fiduciary role in other board, society, committee, or advocacy group participation aschair of the MR Linac consortium, Lead genitourinary editor for IJROBP, and UK Stereotactic Ablative Radiotherapy consortium executive within the past 36 months. MG declares grants or contracts from Varian, AstraZeneca, and ViewRay; payment or honoraria for lectures, presentations, speaker's bureaus, manuscript writing, and educational events from AstraZeneca; and participation on advisory panels for AstraZeneca. MS reports grants or contracts from Varian within the past 36 months. RK declares grants or contracts from Medtronic, Blue Earth Diagnostics, NovoCure, GT Medical Technologies, AstraZeneca, Exelixis, Viewray, Brainlab, Cantex Pharmaceuticals, and Ion Beam Applications; consulting fees from Kazia Therapeutics, Elekta, Viewray, Castle Biosciences, and NovoCure; payment or honoraria for lectures, presentations, speaker's bureaus, manuscript writing, or educational events from Elekta, Accuray, Novocure, Viewray, Elsevier, BrainLab, Peerview Institute for Medical Education, and Ion Beam Applications; support for attending meetings and travel from Elekta, Accuray, Novocure, Peerview Institute for Medical Education, Brainlab, and Viewray; and has participated on a data safety monitoring board or advisory board for Viewray and GT Medical Technologies during the past 36 months. SSL declares grants and contracts from Kuni Foundation and the Hutchinson Center; support for attending meetings and travel from the Japanese Society for Radiation Oncology; a leadership or fiduciary role on the Radiosurgery Society board and as Assistant Councillor and Chair of the CARROS Nominating Committee of the American College of Radiology during the past 36 months. SS received salary support from Cancer Council Victoria via the Colebatch Fellowship; grants or contracts from Varian, Bayer Pharmaceuticals, Merck Sharp & Dohme; payment or honoraria for lectures, presentations, speaker's bureaus, manuscript writing, or educational events from AstraZeneca, Varian, and Roche Pharmaceuticals; a leadership or fiduciary role on the American Society of Radiation Oncology Science Council and the Advanced Radiotherapy Techniques committee of the International Association for the Study of Lung Cancer; and is on the board of directors of the Radiosurgery Society, within the past 36 months. BJS, MA, MNB, M-SK, and ZZ declare no competing interests., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.